0001108205-24-000055.txt : 20240523
0001108205-24-000055.hdr.sgml : 20240523
20240523161221
ACCESSION NUMBER: 0001108205-24-000055
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240521
FILED AS OF DATE: 20240523
DATE AS OF CHANGE: 20240523
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Duvall Diantha
CENTRAL INDEX KEY: 0001696784
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30347
FILM NUMBER: 24978341
MAIL ADDRESS:
STREET 1: C/O GENOCEA BIOSCIENCES, INC.
STREET 2: 100 ACORN PARK DRIVE 5TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CURIS INC
CENTRAL INDEX KEY: 0001108205
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 043505116
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SPRING STREET
STREET 2: BUILDING C, SUITE 500
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-503-6500
MAIL ADDRESS:
STREET 1: 128 SPRING STREET
STREET 2: BUILDING C, SUITE 500
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
wk-form4_1716495126.xml
FORM 4
X0508
4
2024-05-21
0
0001108205
CURIS INC
CRIS
0001696784
Duvall Diantha
128 SPRING STREET
BUILDING C - SUITE 500
LEXINGTON
MA
02421
0
1
0
0
CFO
0
Employee stock option (right to buy)
11.62
2024-05-21
4
A
0
39000
11.62
A
2034-01-18
Common Stock
39000
39000
D
This option grant, as disclosed in Curis Inc.'s 2024 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 19, 2024, contingent upon shareholder approval of Curis's Fifth Amended and Restated 2010 Stock Incentive Plan to, among other things, increase the number of shares authorized for issuance thereunder and increase the per participant limit on the number of shares subject to awards that can be granted annually to participants in the plan; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 21, 2024, at the 2024 annual meeting of shareholders, Curis's shareholders approved the Fifth Amended and Restated 2010 Plan.
The option grant described in this Form 4 filing vests as to 25% of the original shares on January 19, 2025 and as to an additional 6.25% of the original shares each successive quarter and until January 19, 2028.
/s/ Diantha Duvall, Attorney-in-fact
2024-05-23